Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI — ESKETAM  

Depression Anxiety Disorder Clinical Trial

Official title: Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective Monoamine Oxidase Inhibitors (MAOIs)

Status Completed

Clinical Trial Summary

There are already recently published data on the tolerability and efficacy of the combination of ketamine and/or esketamine with MAOIs. However, these reports are few and far between, and to our knowledge, there are no data involving intranasal esketamine.

Given the numerous interactions between MAOIs and other antidepressants, and the impossibility of combination, this pharmacological class is neglected. This is despite the fact that MAOIs are the only truly tri-aminergic drugs, that they have unparalleled efficacy in certain forms of resistant apathetic depression, and that new, more dietary permissive forms have appeared on the market. The arrival of antidepressants that can be combined with MAOIs, such as ketamine and esketamine, changes the situation and could offer a new treatment opportunity to many patients in a therapeutic impasse. For these opportunities to become a reality, sharing the clinical experience gained by specialized centers is essential.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Anxiety Disorders
• Depression
• Depression Anxiety Disorder

• NCT number: NCT05530668
• Study type: Observational
• Source: University Hospital, Strasbourg, France
• Status: Completed
• Start date: April 11, 2022
• Completion date: December 11, 2022